NasdaqGS - Nasdaq Real Time Price USD
LENZ Therapeutics, Inc. (LENZ)
25.79
+1.68
+(6.97%)
At close: 4:00:02 PM EDT
24.89
-0.90
(-3.49%)
After hours: 6:07:39 PM EDT
Insider Purchases Last 6 Months
| Shares | Transactions | |
|---|---|---|
| Purchases | 0 | 0 |
| Sales | -- | 0 |
| Net Shares Purchased (Sold) | 0 | 0 |
| Total Insider Shares Held | 775.88k | -- |
| % Net Shares Purchased (Sold) | -- | -- |
Net Institutional Purchases Prior Quarter to Latest Quarter
| Shares | |
|---|---|
| Net Shares Purchased (Sold) | -- |
| % Change in Institutional Shares Held | -- |
Insider Transactions Reported - Last Two Years
| Insider | Transaction | Type | Value | Date |
|---|---|---|---|---|
| OLSSON SHAWN Officer | Conversion of Exercise of derivative security at price 2.08 per share. | Direct | 2,912 | Apr 9, 2025 |
| SCHIMMELPENNINK EVERT B. Chief Executive Officer | Conversion of Exercise of derivative security at price 1.04 per share. | Direct | 4,368 | Mar 7, 2025 |
| OLSSON SHAWN Officer | Conversion of Exercise of derivative security at price 2.08 per share. | Direct | 6,933 | Dec 16, 2024 |
| SCHIMMELPENNINK EVERT B. Chief Executive Officer | Conversion of Exercise of derivative security at price 1.04 per share. | Direct | 46,800 | Jul 22, 2024 |
| CHEVALLARD DANIEL R Chief Financial Officer | Purchase at price 15.68 per share. | Direct | 49,988 | May 14, 2024 |
| MCCOLLUM JAMES W Director | Purchase at price 15.99 per share. | Indirect | 501,093 | May 13, 2024 |
| RA CAPITAL MANAGEMENT, L.P. Beneficial Owner of more than 10% of a Class of Security | Purchase at price 2.15 per share. | Indirect | 2,145,719 | Mar 21, 2024 |
| RA CAPITAL MANAGEMENT, L.P. Beneficial Owner of more than 10% of a Class of Security | Stock Award(Grant) at price 0.00 per share. | Indirect | 0 | Mar 21, 2024 |
| MCCOLLUM JAMES W Director | Stock Award(Grant) at price 0.00 - 2.15 per share. | Indirect | 35,761 | Mar 21, 2024 |
| ODRICH MARC Officer | Stock Award(Grant) at price 0.00 per share. | Direct | 0 | Mar 21, 2024 |
Related Tickers
BCAX Bicara Therapeutics Inc.
13.82
+9.25%
ANAB AnaptysBio, Inc.
21.58
+4.66%
PTCT PTC Therapeutics, Inc.
48.19
0.00%
CNTA Centessa Pharmaceuticals plc
12.67
+4.28%
PRAX Praxis Precision Medicines, Inc.
35.98
+1.81%
RAPP Rapport Therapeutics, Inc.
11.55
+11.27%
DNTH Dianthus Therapeutics, Inc.
21.87
+6.94%
TCRX TScan Therapeutics, Inc.
1.5700
+2.61%
URGN UroGen Pharma Ltd.
10.05
+4.04%
JANX Janux Therapeutics, Inc.
30.01
+2.42%